← Leaderboards
Xin Ming
Wake Forest University Health Sciences
$2,826,302
Attributed
$3,032,259
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $667.3K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,032,259 · 5
By mechanism
R21$1,628,009 · 4
R01$1,404,250 · 1
Top collaborators
- Shaomin Tian2 shared
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- Douglas G Ririe$2,170,277
- Carl D Langefeld$5,554,144
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCancer CellMalignant NeoplasmsTumor MicroenvironmentLinkResistanceToxic EffectAnti-CancerAnticancer ActivityIn VivoResponseMedicineNeoplasm MetastasisPharmaceutical PreparationsTherapy ResistantCellsSiteCancer TherapyNanoparticleTargeted DeliveryImmunotherapyImmunotherapeutic AgentExtracellularNormal Tissue Morphology
Grant awards (14)
ATP-responsive Nanoparticles for Reversal of Immune Evasion in Breast Cancer$181,390
R21 · FY2025 · CA · contact PI
ATP-responsive Nanoparticles for Reversal of Immune Evasion in Breast Cancer$230,525
R21 · FY2024 · CA · contact PI
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer$193,750
R21 · FY2023 · DE · contact PI
Stimuli-responsive Delivery of Ectonucleotidase Inhibitors to Reprogram Immunometabolism in Head and Neck Cancer$177,534
R21 · FY2023 · CA · contact PI
Targeted Anchoring Ecto-enzyme on Cancer Cell Surface to Enhance Antibody Therapy in Breast Cancer$177,534
R21 · FY2023 · CA · contact PI
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer$232,500
R21 · FY2022 · DE · contact PI
Stimuli-responsive Delivery of Ectonucleotidase Inhibitors to Reprogram Immunometabolism in Head and Neck Cancer$217,388
R21 · FY2022 · CA · contact PI
Targeted Anchoring Ecto-enzyme on Cancer Cell Surface to Enhance Antibody Therapy in Breast Cancer$217,388
R21 · FY2022 · CA · contact PI
Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy$283,650
R01 · FY2020 · CA · contact PI
Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy$275,140
R01 · FY2019 · CA · contact PI
Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy$283,650
R01 · FY2018 · CA · contact PI
Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy$283,650
R01 · FY2017 · CA · contact PI
Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy$193,994
R01 · FY2016 · CA · contact PI
Combination Therapy of OvCa with Oligonucleotides and Photodynamic Therapy$84,166
R01 · FY2016 · CA · contact PI